Why didn't it work?

Comment

Noah M Ivers. CMAJ. 2010.

. 2010 Feb 9;182(2):175.

doi: 10.1503/cmaj.110-2020.

No abstract available

Comment on

The Enhancing Secondary Prevention in Coronary Artery Disease trial.
McAlister FA, Fradette M, Majumdar SR, Williams R, Graham M, McMeekin J, Ghali WA, Tsuyuki RT, Knudtson ML, Grimshaw J. McAlister FA, et al. CMAJ. 2009 Dec 8;181(12):897-904. doi: 10.1503/cmaj.090917. Epub 2009 Nov 23. CMAJ. 2009. PMID: 19933787 Free PMC article. Clinical Trial.

CRP and statins for primary prevention of coronary artery disease.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2008 Dec 15-29;50(1301-1302):97-8; quiz p following 104. Med Lett Drugs Ther. 2008. PMID: 19078864 No abstract available.
Statins.
Kertland H. Kertland H. J Obstet Gynaecol Can. 2003 Mar;25(3):231-4. doi: 10.1016/s1701-2163(16)30111-6. J Obstet Gynaecol Can. 2003. PMID: 12610676 Review.
[Protective effects of pravastatin against atherosclerosis in children with familial hypercholesterolemia].
Riesen WF. Riesen WF. Rev Med Suisse. 2005 Mar 2;1(9):649. Rev Med Suisse. 2005. PMID: 15813344 French. No abstract available.
Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies.
Kreisberg RA, Oberman A. Kreisberg RA, et al. J Clin Endocrinol Metab. 2002 Feb;87(2):423-37. doi: 10.1210/jcem.87.2.8057. J Clin Endocrinol Metab. 2002. PMID: 11836262 Review. No abstract available.
HMG CoA reduction in patients with average cholesterol concentrations.
Braunwald E, Sacks FM, Pfeffer MA, Ridker PM. Braunwald E, et al. Clin Chem. 2011 Jul;57(7):1072-3. doi: 10.1373/clinchem.2011.164038. Epub 2011 Apr 25. Clin Chem. 2011. PMID: 21519035 No abstract available.

1. McAlister FA, Fradette M, Majumdar SR, et al. The Enhancing Secondary Prevention in Coronary Artery Disease trial. CMAJ. 2009;181:897–904. - PMC - PubMed